Journavx, a new non-opioid pain medication, offers a safer alternative for managing acute pain while reducing the risk of ...

Ahead of this weekend's Super Bowl, some good news for the athletes: NFL players are largely avoiding opioid-based pain ...

CenExel, a leading network of clinical research sites, proudly congratulates and announces its role in supporting Vertex Pharmaceuticals’ clinical studies that led to the FDA approval of JOURNAVX™ ...

When THC attaches to the receptor, the effect is like an off switch to a light bulb, effectively turning "off" the pain. But ...

Dr. Sanjay Gupta said Tuesday that the approval of a new non-opioid pain medication is “a pretty big deal.” “This is a pretty ...

Librela (bedinvetmab injection) is a monthly injectable monoclonal antibody, for which real-world drug experience data has ...

New gene therapies could transform sickle cell treatment forever. A future without pain crises or hospitalizations may finally be within reach.

The opioid epidemic continues to affect hundreds of thousands of people, but there may be hope for the future with a new, non ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...

Experts with the Cleveland Clinic say the drug has a lot of potential, especially since it is considered nonaddictive.

The drug offers a non-addictive alternative to opioids, marking 'an important public health milestone in acute pain ...